Bipolar disorder therapeutic pipeline analysis is expected to increase on account of increasing instances of issues related to depression and other mental disorders, across the world. Major factors driving the pipeline analysis for bipolar disorder are obesity, stress, incidence of nervous system trauma, depression, low market penetration of medicines as very small number of companies are making an analog. In addition, increasing awareness regarding health issues among people is another major factor fueling the pipeline analysis for bipolar disorder. According to National Alliance of Medical Illness, the prevalence of bipolar disorder has increased and it can occur at any age in life, mostly around 25 years of age. Every year, nearly 2.9% population in the U.S. is diagnosed with bipolar disorder, in which 83% cases are classified as severe. It is equally affecting in both males and females.
Bipolar disorder is also known as manic depressive illness, that causes an unusual alteration in activity levels, mood, energy, and ability to carry out everyday task. Bipolar disorder is categorized into four types. Bipolar I disorder, having symptoms of manic episodes that last till seven days, and sometimes it becomes sever to the extent that the patients need hospital care. Bipolar III disorder is defined by a pattern of hypomanic episodes and depressive episodes. Cyclothymic disorder, is also known as cyclothymia, which is characterized by many periods of hypomanic symptoms, lasting for around two years. Other bipolar disorders, are of a type not related to the above three. Some bipolar disorders are also similar to other sickness such as eating disorder, substance abuse and anxiety disorder. People with bipolar disorder are at high risk of migraine, thyroid diseases, headache, diabetes, obesity, heart disease and physical illness.
Most of the companies are conducting clinical trials for developing compounds to be used in the treatment of bipolar disorder. Janssen Research & Development, LLC, is introducing a compound, JNJ-18038683. The compound is in Phase II clinical stage, and is being tested for its safety and efficacy in an 8-week trial. JNJ-18038683 is a 5-Hydroxytryptamine 7 receptor (5-HT7) antagonist, highly selective and is given orally. JNJ-18038683 mimicks the effect of most antidepressants. Pfizer, Inc., is also testing on safety and efficacy of compound - Ziprasidone, which is given orally to children. Ziprasidone is in Phase III development stage. However, it is approved for the treatment of mania in bipolar disorder and psychosis in schizophrenia. Forest Laboratories, LLC, is developing a compound Cariprazine and is being tested for its safety and efficacy for patients diagnosed with bipolar depression. Cariprazine isdopamine is a D2/D3 receptor partial agonist. Merck Sharp & Dohme Corp., is developing a compound, Asenapine, which is in Phase II clinical development stage. Asenapine is seen effective in patients having mania in bipolar disorder. Asenapine, also showed its efficacy in treating depressive episodes during mania or mixed symptoms. Intra-Cellular Therapies, Inc., is developing a compound ITI-007, which is having serotonin 5-HT2A receptor antagonism, glutamatergic modulation, serotonin reuptake inhibition and dopamine receptor phosphoprotein modulation. ITI-007 is also showing pre-synaptic partial agonist and partial agonistic activity.
Some of the key having a pipeline of bipolar disorder therapeutics include Aequus Pharmaceuticals Inc., ANP Technologies, Inc., AstraZeneca Plc, Convergence Pharmaceuticals Ltd., D-Pharm Ltd., Delpor, Inc., Intas Pharmaceuticals Ltd., Intra-Cellular Therapies, Inc., Johnson & Johnson Private Limited, KemPharm, Inc., Neurocrine Biosciences, Inc., Omeros Corporation, Otsuka Holdings Co., Ltd., Pfizer Inc.